Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Recruiting

Phase 2

ObeldesivirStudy of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Sponsor:

Gilead Sciences

Code:

NCT06784973

Conditions

RSV Infection

Eligibility Criteria

Sex: All

Age: 0 - 5

Healthy Volunteers: Not accepted

Interventions

Obeldesivir

Obeldesivir Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2025-03-25.